Galaxy Biomedical Investment Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 492.023 million compared to CNY 495.707 million a year ago. Operating loss was CNY 200.698 million compared to operating Income of CNY 5.561 million a year ago. Net loss was CNY 187.947 million compared to CNY 4.877 million a year ago. Basic loss per share from continuing operations was CNY 0.1709 compared to CNY 0.0044 a year ago.